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Abstract
Aims The two main symptoms referred by chronic heart failure (HF) patients as the causes of exercise termination during
maximal cardiopulmonary exercise testing (CPET) are muscular fatigue and dyspnoea. So far, a physiological explanation
why some HF patients end exercise because of dyspnoea and others because of fatigue is not available. We assessed whether
patients referring dyspnoea or muscular fatigue may be distinguished by different ventilator or haemodynamic behaviours
during exercise.
Methods and results We analysed exercise data of 170 consecutive HF patients with reduced left ventricular ejection frac-
tion in stable clinical condition. All patients underwent maximal CPET and a second maximal CPET with measurement of car-
diac output by inert gas rebreathing at peak exercise. Thirty-eight (age 65.0 ± 11.1 years) and 132 (65.1 ± 11.4 years) patients
terminated CPET because of dyspnoea and fatigue, respectively. Haemodynamic and cardiorespiratory parameters were the
same in fatigue and dyspnoea patients. VO2 was 10.4 ± 3.2 and 10.5 ± 3.3 mL/min/kg at the anaerobic threshold and
15.5 ± 4.8 and 15.4 ± 4.3 at peak, in fatigue and dyspnoea patients, respectively. In fatigue and dyspnoea patients, peak heart
rate was 110 ± 22 and 114 ± 22 beats/min, and VE/VCO2 and VO2/work relationship slopes were 31.2 ± 6.8 and 30.6 ± 8.2 and
10.6 ± 4.2 and 11.4 ± 5.5 L/min/W, respectively. Peak cardiac output was 6.68 ± 2.51 and 6.21 ± 2.55 L/min (P = NS for all).
Conclusions In chronic HF patients in stable clinical condition, fatigue and dyspnoea as reasons of exercise termination do
not highlight different ventilatory or haemodynamic patterns during effort.
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Introduction
In apparently healthy subjects and in patients with
suspected cardiac disease, self-reported exercise-induced
dyspnoea has been shown to identify a subgroup of subjects
at higher risk of cardiovascular death in several1–3—albeit
not all—reports.4 Muscular fatigue and dyspnoea are the
two main symptoms that are referred by chronic heart
failure (HF) patients as the cause of exercise limitation. How-
ever, the role of dyspnoea at peak exercise as associated with
prognosis is presently unclear in this setting, as only few
studies have evaluated this issue, and with contradictory re-
sults. Indeed, in a report by Chase et al.,5 exercise dyspnoea
has been linked to a poorer exercise performance and a
higher risk of adverse cardiovascular events, while in the se-
ries of HF patients of Witte et al.,6 no differences in peak VO2
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and prognosis were observed when comparing patients with
and without dyspnoea as exercise limiting symptom.
The cause of exercise-induced dyspnoea in HF patients has
also been studied, but a clear physiological explanation is not
available. In their pioneering work, Wilson and Mancini7 sug-
gested that exercise dyspnoea in HF is due to increased respi-
ratory muscle work mediated by excessive ventilation and
decreased lung compliance. Moreover, Nanas et al.8 reported
a correlation between inspiratory capacity and wedge pres-
sure, and both were associated with exercise performance.
Differently, Russel et al.9 were unable to show a correlation
between dyspnoea and lung function at rest and during exer-
cise in HF patients. According to the study by Nanas et al.,8
we observed a strong correlation between pulmonary func-
tion and exercise performance and, after a therapeutic inter-
vention, an improvement of both pulmonary function and
exercise performance, but not of alveolar capillary membrane
gas diffusion.10–13 However, in all these studies,8,10–12 no cor-
relation was reported between lung function abnormalities
and exercise dyspnoea. So even at present, the reason why
some HF patients end their exercise performance because
of dyspnoea and other because of fatigue is basically un-
known.14 Accordingly, we analysed whether patients refer-
ring dyspnoea or fatigue as the cause of exercise limitation
are characterized by a different ventilatory or haemodynamic
behaviour during exercise. Speciﬁcally, we studied the behav-
iour of exercise performance, ventilatory pattern, and cardiac
output (CO) in 170 consecutive HF patients who performed a
maximal standard cardiopulmonary exercise testing (CPET)
and a second maximal CPET to measure CO (CPET-CO) at rest
and at peak exercise by inert gas rebreathing (IGR).
Methods
Patient population
We retrospectively analysed the clinical data, obtained as
part of the routine HF follow-up program, of 170 consecutive
patients (146 men and 24 women) who underwent full clini-
cal evaluation at our HF unit. All patients underwent both
CPET and CPET-CO within 2 months (16 ± 15 days). Patients
belong to a cohort of HF patients regularly followed up at
our HF unit. All were in stable clinical condition, in New York
Heart Association (NYHA) functional class I–III, capable of
performing standard CPET and rebreathing manoeuvres.
We excluded from data analysis HF patients with pre-
served left ventricular ejection fraction (LVEF) (>50% at
echocardiography), and patients with primary pulmonary hy-
pertension and pulmonary embolism or any disease, which
per se inﬂuenced their exercise capacity.
Heart failure aetiology was as follows: ischaemic heart dis-
ease (35 patients), idiopathic cardiomyopathy (114 patients)
and valvular heart disease (21 patients).
For the present analysis, we evaluated NYHA class, resting
haemoglobin, brain natriuretic peptide, conventional
two-dimensional and Doppler echocardiography, standard
spirometry, CPET, and CPET-CO. Spirometry was performed
according to current guidelines with a mass ﬂow-meter
(SensorMedics, Yorba Linda, CA, USA).15 Predicted values
were calculated according to Quanjer et al.16
Cardiopulmonary exercise testing
A maximal CPET was performed (229D Spectra metabolic cart,
SensorMedics) on a cycle ergometer in patients without con-
traindications to the test (Erg 800S, SensorMedics), using a
personalized ramp protocol aimed at achieving peak exercise
in around 10 min. The majority of these patients had
previously undergone a CPET in our laboratory; the other
patients underwent a familiarization procedure. We analysed
CPET using a standard methodology. All CPETs were per-
formed by a cardiology expert on CPET, a fellow, and a dedi-
cated nurse. CPET was self-interrupted by the patients when
he or she claimed that he or she had reached amaximal effort.
We systematically asked the patients the reason why the pro-
cedure was terminated and if it was speciﬁcally because of
chest pain, dyspnoea, or fatigue. Peak VO2 was calculated as
an average over 30 s and reported either as absolute value
or as a percentage of the VO2 max predicted value.
17 The O2
pulse was calculated as VO2/heart rate (HR). The VO2/work
relationship was calculated through the entire exercise, while
the ventilation (VE)/carbon dioxide ﬂow (VCO2) slope was cal-
culated as the slope of the relationship between VE and VCO2
from approximately 1 min after the beginning of loaded exer-
cise to the end of the isocapnic buffering period.18
A CPET-CO was performed using the same ramp protocol
of CPET. CO was measured at rest and at peak exercise using
an IGR method19–21 that required a few teaching sessions to
familiarize patients with the necessary manoeuvre. The IGR
technique has been previously reported in detail.19 In brief,
the IGR technique uses an oxygen-enriched mixture of an in-
ert soluble gas (0.5% nitrous oxide) and an inert insoluble gas
(0.1% sulfur hexaﬂuoride) inﬂated into a bag by the machine.
Patients have to breathe into a respiratory valve via a mouth-
piece and a bacterial ﬁlter with a nose clip. At the end of ex-
piration, the valve is activated automatically so that patients
rebreathe from the preﬁlled bag for a period of 10 to 20 s. Af-
ter that period, patients start breathing ambient air again. CO
measurement is performed by a photo-acoustic analyser that
measures gas concentration over a ﬁve-breath interval. Sulfur
hexaﬂuoride, which is insoluble in blood, is used to deter-
mine lung volume, while the concentration of nitrous oxide,
which is soluble in blood, decreases during rebreathing with
a rate that is proportional to pulmonary blood ﬂow. CO is
equal to pulmonary blood ﬂow only if the arterial oxygen sat-
uration (SpO2) measure is >98% at pulse oximeter, showing
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the absence of pulmonary shunt ﬂow. If SpO2 is <98%, CO is
equal to pulmonary blood ﬂow plus shunt ﬂow.19 In CPET-CO,
respiratory gases and ventilation were measured breath by
breath as in CPET.
Arterio-venous O2 content differences [ΔCO2(a-v)] was cal-
culated as VO2/CO.
Both CPETs were performed as part of the clinical evalua-
tion that we routinely perform at our HF unit. We obtained
written informed consent before each CPET for the exercise
procedure as well as for the blind research use of CPET de-
rived data as well as for all patients’ clinical data. The present
retrospective study was reviewed and approved by our insti-
tutional review board (Centro Cardiologico Monzino ethics
committee) before the study began.
Statistical analysis
Continuous variables were expressed as means ± standard de-
viation, or as median and interquartile range if not normally
distributed. Comparisons between the two groups were per-
formed using unpaired t-tests for normally distributed vari-
ables, and Mann–Whitney U-test for non-normally distributed
variables. P < 0.05 was considered statistically signiﬁcant.
Statistical analysis was performed using SPSS 23.0 software
(SPSS Inc., Chicago, IL, USA).
Results
We studied a cohort of 170 patients in NYHA class I, n = 42
(25%); II, n = 93 (55%); and III, n = 35 (20%). Patients’ age
was 65 ± 11 years, and 86% were male. Average LVEF was
31 ± 8%. Spirometry showed forced expiratory volume in 1 s
is equal to 82.8 ± 18.0% of the predicted value and forced vital
capacity equal to 88.2 ± 16.9% of the predicted value. Thirty-
eight patients terminated the CPET procedure because of dys-
pnoea, and 132 because of muscular fatigue. The mean ramp
protocol used was 9.03 ± 3.3 W/min in both exercise tests.
The duration of the tests was 9.3 ± 1.7 and 9.1 ± 2.7 min (av-
erage work rate = 83.4 ± 33.4 W) in CPET and CPET-CO, respec-
tively. Peak exercise respiratory gas exchange was 1.14 ± 0.11
in CPET, showing that, on average, patients performed a max-
imal or nearly maximal exercise test in both CPETs.
The cardiorespiratory performance was analysed during
CPET to avoid any possible interference of the rebreathing
manoeuvre with ventilation and respiratory gases. The anaer-
obic threshold was identiﬁed in 94% of patients. At anaerobic
threshold, VO2 was 0.80 ± 0.29 L/min (10.2 ± 3.2 mL/kg/min),
HR was 90 ± 16 beats/min, and end-tidal pCO2 was
35.1 ± 4.1 mmHg. At peak exercise, VO2 was 1.2 ± 0.4 L/min
corresponding to 15.5 ± 4.7 mL/kg/min and to 61.8 ± 18.4%
of the predicted value; HR was 111 ± 22 beats/min; and oxy-
gen pulse was 11.4 ± 5.7 mL/min. The slopes of VE/VCO2 and
VO2/work relationship were 31.1 ± 7.1 and 10.8 ± 4.6 L/min/
W, respectively.
Patients were grouped according to the reason (muscular fa-
tigue or dyspnoea) that led them to terminate the procedure
(Table 1). No difference was observed in terms of all analysed
parameters derived from CPET and CPET-CO (Table 2).
Patients’ data were included in the MECKI score dataset.22
Cardiovascular mortality was low at 1 year (only two cases in
the muscular fatigue group), conﬁrming that patients were in
stable clinical condition and optimized drug treatment.
Discussion
The main ﬁnding of the present study is that 22% of patients
ended the effort because of dyspnoea and 78% because of fa-
tigue. Patients ending a maximal effort because of dyspnoea
had the same peak VO2, peak HR, peak CO, ΔCO2(a-v), and
VE/VCO2 slope as those ending their exercise because of
fatigue.
We analysed data of HF patients in stable clinical conditions
who performed two CPETs and excluded those who performed
Table 1 General characteristics of patients who interrupted exer-
cise because of muscular fatigue and those who did because of
dyspnoea
ACE, angiotensin converting enzyme; ARB, angiotensin receptor
blockers; BMI, body mass index; BNP, brain natriuretic peptide; FEV1,
forced expiratory volume in 1 s; FVC, forced vital capacity; LVeDV, left
ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVeSV, left ventricular end-systolic volume; NYHA, New York Heart
Association; PAPs, pulmonary artery systolic pressure.
Patients were grouped according to the reason (muscular fatigue or
dyspnoea) that led them to terminate the procedure. No difference
was observed in terms of all analysed parameters. Data are expressed
as mean ± standard deviation or as median (25th–75th quartile).
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only CPET-CO or with a time lag between the two tests
>2 months. The ﬁrst test was used to assess the metabolic pa-
rameters during exercise and the cause of exercise termination;
the second one, CPET-CO, to measure CO by IGR. We chose this
dual investigational strategy to avoid any possible interference
of the rebreathing manoeuvre with the exercise performance
and the sensation of dyspnoea. Indeed, we feared that the
rebreathing manoeuvre, which requires an inspiration followed
by ﬁve regular breaths at a ﬁxed rate (usually 30 breath/min at
peak exercise), might generate dyspnoea and somehow affect
exercise performance. As a matter of fact, exercise tolerance
was the same at both tests.
The percent of HF patients referring dyspnoea as the cause of
exercise limitation varies among studies.6,9,23 In the present
study, we observed that the ﬁrst cause for self-ending a maximal
effort referred by patients with chronic HF is fatigue (78% of
cases), and dyspnoea was reported in 22% of cases. It should
be noticed that our patients belong to a cohort HF regularly
followed up at our HF unit, who were all in stable clinical condi-
tion and on optimal treatment; and, consequently, ﬂuid balance
was likely optimal, and that almost all had had previous experi-
ence of CPET in our laboratory, likely reducing test-induced anx-
iety, which is more likely associated with dyspnoea.
Patients referring dyspnoea as the cause of exercise termina-
tion showed, at peak exercise and at the anaerobic threshold,
data similar to those recorded in patients who referred fatigue
as the cause of exercise limitation. Also the VO2/work relation-
ship, an index of the efﬁciency of O2 delivery to the periphery,
was similar. This datum, combined with direct CO measurement
and calculated ΔCO2(a-v), reinforces the concept of a similar
haemodynamic behaviour during exercise. Moreover, the symp-
tom referred by the patients as the cause of exercise termination
was unrelated to HF severity or characteristics as evaluated by
NYHA class, LVEF, haemoglobin concentration, or peak VO2.
It is of note that neither resting spirometry nor ventilatory
parameters during exercise were able to differentiate pa-
tients who stopped exercise because of dyspnoea from those
who stopped because of fatigue. In particular, neither the
VE/VCO2 slope, a parameter of ventilatory efﬁciency known
to increase in case of pulmonary hypertension, nor the VE in-
tercept of the VE/VCO2 relationship, which increases in case
of respiratory co-morbidities in HF patients, was different.24
It is therefore likely that the different symptoms referred
are related to the individually built central reconstruction of
similar peripheral signals, making impossible for the patients
to differentiate between dyspnoea and fatigue or between
central and peripheral exercise ending causes.
A few study limitations should be acknowledged. First of
all, we have not tested the repeatability of the symptom
referred as the cause of exercise termination by the patients.
Similarly, in the present setting of patients, repeatability of
peak CO was not tested, albeit IGR precision and repeatability
have been previously shown.19–21 Finally neither a Borg
dyspnoea scale nor Borg Rating of Perceived Exertion scale
was obtained at the end of each CPET.
In conclusion, in chronic HF patients in stable clinical condi-
tion and on optimal treatment, fatigue and dyspnoea as causes
of exercise termination during self-interrupted CPET do not un-
derscore different cardiorespiratory or haemodynamic
patterns.
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Table 2 Difference of exercise parameters between patients who
interrupted exercise because of muscular fatigue and those who
did because of dyspnoea
Variables
Muscular fatigue
(n = 132)
Dyspnoea
(n = 38)
P
value
Ramp protocol 10 (6–12) 8 (6–10) 0.13
Test length, min 9.22 ± 1.72 9.68 ± 1.80 0.19
Achievement of AT, % 94 95 0.85
VO2 at AT, L/min 0.82 ± 0.29 0.81 ± 0.30 0.91
VO2 at AT, mL/kg/min 10.4 ± 3.2 10.5 ± 3.3 0.59
HR at AT, beats/min 89 ± 15.1 93 ± 17 0.19
Work at AT, W 48.9 ± 21.7 48.7 ± 24.8 0.98
Peak VO2, L/min 1.21 ± 0.43 1.14 ± 0.41 0.38
Peak VO2, mL/kg/min 15.49 ± 4.77 15.35 ± 4.34 0.87
Peak VO2, % of predicted 61.8 ± 18.6 62.1 ± 19.7 0.88
Peak HR, beats/min 110 ± 22 114 ± 22 0.30
Peak HR, % of predicted 72 ± 13.4 74.7 ± 14.2 0.28
Work at peak, W 84.5 ± 33.2 79.6 ± 34.3 0.43
Peak O2 pulse, mL/beat 11.8 ± 6.2 10.2 ± 3 0.12
VE/VCO2 slope 31.2 ± 6.8 30.6 ± 8.2 0.65
Peak PetCO2, mmHg 32.4 ± 4.7 31.3 ± 4.5 0.20
Y intercept, L/min 3.73 ± 2.33 4.11 ± 3.23 0.47
VO2/work slope, L/min/W 10.6 ± 4.2 11.4 ± 5.5 0.34
Peak Vt, L 1.7 ± 0.5 1.7 ± 0.6 0.87
Peak VE, L 52.5 ± 16.7 51.7 ± 15.5 0.81
Breathing reserve, % 42.3 ± 15.3 43 ± 15.8 0.83
Respiratory rate,
breath/min
31.4 ± 7.5 31.1 ± 7.2 0.78
RER 1.14 ± 0.11 1.14 ± 0.10 0.87
Baseline CO, L/min 3.26 ± 0.98 3.12 ± 0.92 0.43
Peak CO, L/min 6.68 ± 2.51 6.21 ± 2.55 0.32
Peak CO, % of predicted 51.6 ± 14.7 49.4 ± 16.9 0.44
Baseline SV, L/min 48.5 ± 15.1 46.6 ± 14 0.48
Peak SV, L/min 64.5 ± 21.2 58.3 ± 16.2 0.10
Peak SV, % of predicted 78.2 ± 21.6 74.5 ± 19.6 0.36
Baseline ΔCO2(a-v),
mL/100 mL
9.87 ± 3.2 10.1 ± 2.7 0.74
Peak ΔCO2(a-v),
mL/100 mL
18.2 ± 3.8 18.2 ± 3.6 0.98
Peak ΔCO2(a-v), %
of predicted
120 ± 26.8 123 ± 27.9 0.65
AT, anaerobic threshold; CO, cardiac output; HR, heart rate; Pet,
pressure end-tidal; RER, respiratory gas exchange ratio; SV, stroke
volume; VE, minute ventilation; VE/VCO2, ventilatory efﬁciency;
VO2, oxygen uptake; Vt, tidal volume; ΔCO2(a-v), arterio-venous
oxygen difference.
Patients were grouped according to the reason (muscular fatigue
or dyspnoea) that led them to terminate the procedure. No differ-
ence was observed in terms of all analysed parameters. Data are
expressed as mean ± standard deviation or as median (25th–
75th quartile).
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